Emerging data on nivolumab for esophageal squamous cell carcinoma.

Toshiharu HiroseShun YamamotoKen Kato

Published in: Expert review of gastroenterology & hepatology (2021)

Nivolumab has been approved by the US Food and Drug Administration for treatment after prior chemotherapy in patients with advanced ESCC. Several trials evaluating nivolumab-containing treatments are ongoing in patients with not only advanced EC, but also locally advanced EC, and these investigational treatments might improve the clinical outcomes of EC patients.

Keyphrases

drug administration
locally advanced
end stage renal disease
squamous cell carcinoma
ejection fraction
rectal cancer
newly diagnosed
chronic kidney disease
neoadjuvant chemotherapy
prognostic factors
electronic health record
risk assessment
lymph node
human health
combination therapy
study protocol